Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus

European Respiratory Journal

Volumn 16, Issue 4, 2000, Pages 749-767

  Doring, G ^a   Conway, S P ^a   Heijerman, H G M ^a   Hodson, M E ^a   Hoiby, N ^a   Smyth, A ^a   Touw, D J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antibiotic therapy; Consensus; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; MEROPENEM; NETILMICIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CYSTIC FIBROSIS; DISEASE COURSE; EUROPE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION PREVENTION; INTERNATIONAL COOPERATION; MEDICAL EXPERT; NEBULIZATION; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; PSEUDOMONAS INFECTIONS;

EID: 0033773012     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.16d30.x     Document Type: Review

References (196)

1. The epidemiology of cystic fibrosis
2. Basic molecular biology
3. The pathology of cystic fibrosis
4. Lower airway inflammation in infants and young children with cystic fibrosis
5. Early pulmonary inflammation in infants with cystic fibrosis
6. Epidemiology and ecology of Pseudomonas aeruginosa
7. Microbiology of lung infections in cystic fibrosis patients
8. Qualitatssicherung Mukoviszidose. Zentrum fur Qualitatsmanagement im Gesundheitswesen
9. Pseudomonas aeruginosa infection in cystic fibrosis and its management
10. Nebulised antibiotics for adults with cystic fibrosis
11. Pseudomonas aeruginosa vaccines
12. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis - Three year results
13. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis
14. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis
15. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis
16. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
17. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages
18. Immunology of cystic fibrosis
19. Microbiology of cystic fibrosis
20. Pseudomonas and Burkholderia
21. Cystic fibrosis: A review of pulmonary infections and interventions
22. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis
23. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients
24. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis
25. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients
26. Progression of pulmonary disease after disappearance of Pseudomonas in cystic fibrosis
27. Determinants of mortality from cystic fibrosis in Canada, 1970-1989
28. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
29. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis
30. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
31. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
32. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
33. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment
34. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa
35. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
36. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms
37. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
38. High-level betalactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment
39. Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis
40. Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987
41. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
42. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
43. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
44. Aerosolized tobramycin in patients with cystic fibrosis
45. Safely of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
46. Microbology effect at 18 months of intermittant inhaled tobramycin in patients with CF
47. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
48. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa
49. Long-term tobramycin therapy in cystic fibrosis
50. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: The results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology
51. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center
52. Antibiotic resistance of Pseudomonas aeruginosa
53. Spread of betalactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
54. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
55. What is an antibiotic?
56. Controlled trial of ceftazidime vs. Ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis
57. Development of Pseudomonas aeruginosa strains resistant to carbenicillin, azlocillin, piperacillin and tobramycin during chemotherapy in cystic fibrosis patients
58. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
59. Penetration of antibiotics into respiratory secretions
60. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree
61. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis
62. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions
63. Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage
64. Pharmacokinetics of quinolones with special reference to the respiratory tree
65. Pharmacokinetics of antibiotics in the lungs
66. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis
67. Inhaled antibiotics in cystic fibrosis: A review
68. Pharmacokinetics of antimicrobial drugs in cystic fibrosis; β-lactam antibiotics
69. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis
70. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
71. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis
72. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit
73. Macromolecular mechanisms of sputum inhibition of tobramycin activity
74. Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study
75. Antibiotic activity in sputum
76. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum
77. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material
78. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro
79. Interference of ciprofloxacin with the expression of pathogenicity factors of Pseudomonas aeruginosa
80. Inhibition of Pseudomonas aeruginosa exoenzyme expression by sub-inhibitory antibiotic concentrations
81. Pseudomonas aeruginosa virulence factors: Modifications by sub-inhibitory concentrations of carbenicillin or gentamycin
82. Effect of antibiotics on production of enzymes and toxins by microorganisms
83. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas
84. Pharmacokinetics of meropenem in patients with cystic fibrosis
85. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance
86. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study
87. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis
88. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis
89. Drug disposition in cystic fibrosis: Progress in understanding pathophysiology and pharmacokinetics
90. Pharmacokinetics of drugs in cystic fibrosis
91. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment
92. Pharmacokinetics of ciprofloxacin in cystic fibrosis
93. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
94. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis
95. Randomized doubleblind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis
96. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burholderia cepacia with hypersensitivity to β-lactam antibiotics
97. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
98. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model
99. Once-daily vs. Continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
100. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis
101. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis
102. Adverse reactions to piperacillin in adults with cystic fibrosis
103. Denmark to the rescue
104. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa
105. Long-term azithromycin may improve lung function in children with cystic fibrosis
106. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
107. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms
108. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis
109. Carbenicillin in patients with cystic fibrosis: Clinical pharmacology and therapeutic evaluation
110. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis
111. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis
112. Effect of nebulizer type and antibiotic concentration on device performance
113. The nephropathy of cystic fibrosis: A human model of chronic nephrotoxicity
114. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: Effects of tobramycin
115. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity
116. Symptomatic hypomagnesaemia in cystic fibrosis
117. Evaluation of a once-daily netilmicin regimen in the treatment of cystic fibrosis
118. The occurrence and risk estimate of ototoxicity in CF patients receiving frequent aminoglycoside therapy
119. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis
120. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. Infections in cystic fibrosis patients
121. Safety of aztreonam in patients with cystic fibrosis and allergy to β-lactam antibiotics
122. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other β-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses
123. Drug allergy in cystic fibrosis
124. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis
125. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis
126. Increasing dose regimen in children with reactions to ceftazidime
127. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis
128. In vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients
129. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis
130. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. Ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group
131. Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
132. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
133. Use of quinolones in pediatric patients
134. Oral ciprofloxacin vs. Intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group
135. Quinolone arthropathy in animals versus children
136. Use of fluoroquinolones in pediatrics: Consensus report of an International Society of Chemotherapy commission
137. Pediatric use of quinolones
138. Lung distribution and pharmacokinetics of aerosolized tobramycin
139. Inhalation of antibiotics in cystic fibrosis
140. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa in cystic fibrosis: Current status of the host-bacterium interaction
141. Nebulized gentamicin in children and adolescents with cystic fibrosis
142. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis
143. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
144. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks
145. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis
146. Use of aerosolized antibiotics in patients with cystic fibrosis
147. Evidence for using nebulised antibiotics in cystic fibrosis
148. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis
149. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis
150. Bronchial response to nebulized antibiotics in children with cystic fibrosis
151. Nebulized colistin causes chest tightness in adults with cystic fibrosis
152. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis
153. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis
154. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
155. Inhaled micronised gentamicin powder: A new delivery system
156. Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose
157. Therapeutic aerosols I. Physical and practical considerations
158. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols
159. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand
160. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
161. Relationship between tracheobronchial particle clearance rates and sites of initial deposition in man
162. The quantitative distribution of nebulised antibiotic in the lung in cystic fibrosis
163. Evaluation of jet nebulisers for use with gentamicin solution
164. Droplet size distribution of nebulised aerosols for inhalation therapy
165. Choice of nebulisers and compressors for delivery of carbenicillin aerosol
166. Deposition of carbenicillin aerosols in cystic fibrosis: Effects of nebuliser system and breathing pattern
167. Tobramycin aerosol: Could the delivery system influence the particle size and deposition in the lower airways?
168. Nebulizer delivery of tobramycin to the lower respiratory tract
169. Disposable jet nebulizers: How reliable are they?
170. Inhaled antibiotics in cystic fibrosis: Is there a therapeutic effect?
171. Homogeneity of bronchopulmonary distribution of 99Tc aerosol in normal subjects and in cystic fibrosis patients
172. Radioaerosol assessment of lung inprovement in cystic fibrosis patients treated for acute pulmonary exacerbations
173. Aerosol scintigraphy in the assessment of therapy for cystic fibrosis
174. In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis
175. Clinical indications for and effects of blind, mucolytic and antimicrobial aerosols
176. The carbenicillin potentiating effect of N-acetylcysteine in vitro
177. Recombinant human DNAse I reduces the viscosity of cystic fibrosis sputum
178. N-acetylcysteine and 2-mercaptoethane sulphonate inhibit anti-pseudomonas activity of antibiotics in vitro
179. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation
180. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
181. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
182. Home treatment of pulmonary infection in cystic fibrosis
183. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics
184. Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects
185. Home nebulizer use among patients with cystic fibrosis
186. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
187. Lung disease in cystic fibrosis-an updated concept
188. Denmark to the rescue
189. Aerosoltherapie et mucoviscidose: Enquete nationale
190. Cystie fibrosis: Antibiotie preseribing practices in the United Kingdom and Eire
191. Antibiotie therapy in eystie fibrosis: Evaluation of elinieal trials
192. Negative elinieal trials in eystic fibrosis research
193. Outcome measures for clinical trials in cystic fibrosis. Summary of a cystic fibrosis foundation consensus conference